Inhaled steroids in asthma

Comprehensive Therapy

Volumn 24, Issue 8, 1998, Pages 378-382

  Aronica, Mark ^a   Sheller, J R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CORTICOTROPIN; CROMOGLYCATE DISODIUM; CYTOKINE; FLUNISOLIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID RECEPTOR; GLUCOSE; HYDROCORTISONE; LEUKOTRIENE; MESSENGER RNA; MOMETASONE FUROATE; MONTELUKAST; NEDOCROMIL; NYSTATIN; PREDNISONE; PROSTAGLANDIN SYNTHASE; SALMETEROL; STEROID; THEOPHYLLINE; TRANSCRIPTION FACTOR; TRIAMCINOLONE ACETONIDE; ZAFIRLUKAST; ZILEUTON;

ARTICLE; ASTHMA; CLINICAL TRIAL; DRUG COST; DRUG POTENCY; FORCED EXPIRATORY VOLUME; GROWTH RETARDATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; METERED DOSE INHALER; ORAL DRUG ADMINISTRATION; RECEPTOR OCCUPANCY; THRUSH; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; AGE FACTORS; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; CLINICAL TRIALS; HUMANS; STEROIDS;

EID: 0031880873     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Laitinen LA, Laitinen A. Modulation of bronchial inflammation: corticosteroids and other therapeutic agents. Am J Respir Crit Care Med. 1994;150:S87-90.
2. Dworski RT, Funk CD, Oates JA, Sheller JR. Prednisone increases PGH-synthase 2 in atopic humans in vivo. Am J Respir Crit Care Med. 1997;155:351-357.
3. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 1997;337: 8-14.
4. Toogood JH, Baskerville J, Jennings B, Lefcoe NM, Johansson SA. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol. 1989;84:688-700.
5. Murray JJ, Friedman B, Chervinsky P, Fogarty C, Baker JW, Rogenes PR, et a. Fluticasone is more effective than higher doses of beclomethasone diproprionate in patients with moderate asthma. Am J Respir Crit Care Med. 1998;157: A407.
6. Pauwels RA, Yernault JC, Demedts MG, Geusens P. Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Am J Respir Crit Care Med. 1998;157:827-832.
7. Wilson AM, McFarlane LC, Lipworth BJ. Dose-response effect for adrenal suppression with repeated twice daily inhaled fluticasone propionate and triamcinolone acetonide in adult asthmatics. Am J Respir Crit Care Med. 1997;156: 1274-1277.
8. Clark DJ, Lipworth BJ. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax. 1997;52:55-58.
9. Williams AJ, Baghat MS, Stableforth DE, Cayton RM, Shenoi PM, Skinner C. Dysphonia caused by inhaled steroids: recognition of a characteristic laryngeal abnormality. Thorax. 1983;38:813-821.
10. Williamson IJ, Matusiewicz SP, Brown PH, Greening AP, Crompton GK. Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. Eur Respir J. 1995;8:590-592.
11. Lemanske RF, Allen DB. Choosing a long-term controller medication in childhood asthma. Am J Respir Crit Care Med. 1997;156:685-687.
12. NIH Publication 97-4053, Oct. 1997.
13. Calpin C, MacArthur C, Stephens D, Feldman W, Parkin PC. Effectiveness of prophylactic inhaled steroids in childhood asthma: a systemic review of the literature. J Allergy Clin Immunol. 1997;100:452-457.
14. Price JF, Hindmarsh RG, Weller P, Heaf DP, Williams J. Growth during one year of treatment with fluticasone propionate or sodium cromoglycate in children with asthma. Pediatr Pulmonol. 1997;24:178-186.
15. Bisgaard H. Use of inhaled corticosteroids in pediatric asthma. Pediatr Pulmonol. 1997;15(suppl):27-33.
16. Ukena D, Harnest U, Sakalauskas R, Magyar P, Vetter N, Steffen H, et al. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J. 1997;10:2754-2760.
17. Israel E, Cohn J, Dube L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial. JAMA. 1996;275:931-936.
18. Reiss TF, Sorkness CA, Stricker W, Botto A, Busse WW, Kundu S, et al. Effects of montelukast (MK-0476): a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax. 19978;52:45-48.
19. Fish JE, Kemp JP, Lockey RF, Glass M, Hanby LA, Bonuccelli CM. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. Clin Ther. 1997;19: 675-690.
20. Kane GC, Pollice M, Kim C-J, Cohn J, Dworski RT, Murray JJ, et al. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental allergen challenge in human beings. J Allergy Clin Immunol. 1996;97:646-654.
21. Wenzel SE. Arachidonic acid metabolites; mediators of inflammation in asthma. Pharmacotherapy. 1997;17:3S-12S.
22. Levy ML, Stevenson C, Maslen T. Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care. Thorax. 1996;51:1087-1092.